62 related articles for article (PubMed ID: 16730475)
1. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo.
McCown TJ
Mol Ther; 2006 Jul; 14(1):63-8. PubMed ID: 16730475
[TBL] [Abstract][Full Text] [Related]
2. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB).
Gray SJ; Blake BL; Criswell HE; Nicolson SC; Samulski RJ; McCown TJ; Li W
Mol Ther; 2010 Mar; 18(3):570-8. PubMed ID: 20040913
[TBL] [Abstract][Full Text] [Related]
3. Opposing actions of hippocampus TNFα receptors on limbic seizure susceptibility.
Weinberg MS; Blake BL; McCown TJ
Exp Neurol; 2013 Sep; 247():429-37. PubMed ID: 23333565
[TBL] [Abstract][Full Text] [Related]
4. Revoking the Seize Order: Preventing Spontaneous Seizures With AAV in a CLN2 Mouse Model.
Buchanan GF
Epilepsy Curr; 2023; 23(6):386-388. PubMed ID: 38269343
[No Abstract] [Full Text] [Related]
5. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo.
Foti S; Haberman RP; Samulski RJ; McCown TJ
Gene Ther; 2007 Nov; 14(21):1534-6. PubMed ID: 17713567
[TBL] [Abstract][Full Text] [Related]
6. Gene and Cell Therapy for Epilepsy: A Mini Review.
Shaimardanova AA; Chulpanova DS; Mullagulova AI; Afawi Z; Gamirova RG; Solovyeva VV; Rizvanov AA
Front Mol Neurosci; 2022; 15():868531. PubMed ID: 35645733
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.
Parambi DGT; Alharbi KS; Kumar R; Harilal S; Batiha GE; Cruz-Martins N; Magdy O; Musa A; Panda DS; Mathew B
Mol Neurobiol; 2022 Jan; 59(1):191-233. PubMed ID: 34655056
[TBL] [Abstract][Full Text] [Related]
8. Insights into Potential Targets for Therapeutic Intervention in Epilepsy.
Zavala-Tecuapetla C; Cuellar-Herrera M; Luna-Munguia H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202963
[TBL] [Abstract][Full Text] [Related]
9. Epilepsy Gene Therapy Using an Engineered Potassium Channel.
Snowball A; Chabrol E; Wykes RC; Shekh-Ahmad T; Cornford JH; Lieb A; Hughes MP; Massaro G; Rahim AA; Hashemi KS; Kullmann DM; Walker MC; Schorge S
J Neurosci; 2019 Apr; 39(16):3159-3169. PubMed ID: 30755487
[TBL] [Abstract][Full Text] [Related]
10. Altered gene expression profile in a mouse model of SCN8A encephalopathy.
Sprissler RS; Wagnon JL; Bunton-Stasyshyn RK; Meisler MH; Hammer MF
Exp Neurol; 2017 Feb; 288():134-141. PubMed ID: 27836728
[TBL] [Abstract][Full Text] [Related]
11. A Molecular Approach to Epilepsy Management: from Current Therapeutic Methods to Preconditioning Efforts.
Amini E; Rezaei M; Mohamed Ibrahim N; Golpich M; Ghasemi R; Mohamed Z; Raymond AA; Dargahi L; Ahmadiani A
Mol Neurobiol; 2015 Aug; 52(1):492-513. PubMed ID: 25195699
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3α,5α-THP and reduces long-term operant ethanol self-administration.
Cook JB; Werner DF; Maldonado-Devincci AM; Leonard MN; Fisher KR; O'Buckley TK; Porcu P; McCown TJ; Besheer J; Hodge CW; Morrow AL
J Neurosci; 2014 Apr; 34(17):5824-34. PubMed ID: 24760842
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy in epilepsy-is it time for clinical trials?
Kullmann DM; Schorge S; Walker MC; Wykes RC
Nat Rev Neurol; 2014 May; 10(5):300-4. PubMed ID: 24638133
[TBL] [Abstract][Full Text] [Related]
14. Progress in gene therapy for neurological disorders.
Simonato M; Bennett J; Boulis NM; Castro MG; Fink DJ; Goins WF; Gray SJ; Lowenstein PR; Vandenberghe LH; Wilson TJ; Wolfe JH; Glorioso JC
Nat Rev Neurol; 2013 May; 9(5):277-91. PubMed ID: 23609618
[TBL] [Abstract][Full Text] [Related]
15. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy.
Wykes RC; Heeroma JH; Mantoan L; Zheng K; MacDonald DC; Deisseroth K; Hashemi KS; Walker MC; Schorge S; Kullmann DM
Sci Transl Med; 2012 Nov; 4(161):161ra152. PubMed ID: 23147003
[TBL] [Abstract][Full Text] [Related]
16. Viral vectors and delivery strategies for CNS gene therapy.
Gray SJ; Woodard KT; Samulski RJ
Ther Deliv; 2010 Oct; 1(4):517-34. PubMed ID: 22833965
[TBL] [Abstract][Full Text] [Related]
17. Current prospects and challenges for epilepsy gene therapy.
Weinberg MS; McCown TJ
Exp Neurol; 2013 Jun; 244():27-35. PubMed ID: 22008258
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y signaling modulates the expression of ethanol-induced behavioral sensitization in mice.
Hayes DM; Fee JR; McCown TJ; Knapp DJ; Breese GR; Cubero I; Carvajal F; Lerma-Cabrera JM; Navarro M; Thiele TE
Addict Biol; 2012 Mar; 17(2):338-50. PubMed ID: 21762289
[TBL] [Abstract][Full Text] [Related]
19. The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5.
Weinberg MS; Blake BL; Samulski RJ; McCown TJ
Gene Ther; 2011 Oct; 18(10):961-8. PubMed ID: 21490684
[TBL] [Abstract][Full Text] [Related]
20. Adenosine kinase as a target for therapeutic antisense strategies in epilepsy.
Theofilas P; Brar S; Stewart KA; Shen HY; Sandau US; Poulsen D; Boison D
Epilepsia; 2011 Mar; 52(3):589-601. PubMed ID: 21275977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
